Filana Therapeutics Rebrands, Changes Ticker to FLNA, and Refocuses on Filamin A Modulation

summarizeSummary

Cassava Sciences, Inc. has officially changed its name to Filana Therapeutics, Inc. and will trade under the new ticker symbol "FLNA" starting March 11, 2026, reflecting a strategic focus on developing medicines to modulate the filamin A protein for CNS disorders.

check_boxKey Events

• Corporate Rebranding

  Cassava Sciences, Inc. officially changed its legal name to Filana Therapeutics, Inc. effective March 10, 2026.

• New Ticker Symbol

  Effective March 11, 2026, the company's common stock will trade on the Nasdaq Capital Market under the new ticker symbol "FLNA".

• Strategic Focus Shift

  The rebrand reflects a strategic focus on developing novel medicines to modulate the filamin A protein for central nervous system disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy.

• Bylaws Amendments

  Amended and restated By-Laws were adopted, clarifying and modernizing provisions related to stockholder and board meetings, advance notice requirements, director terms, special meetings, inspectors of election, and uncertificated shares.

auto_awesomeAnalysis

This 8-K filing announces a significant corporate rebranding for the company, moving from Cassava Sciences, Inc. to Filana Therapeutics, Inc., along with a new ticker symbol "FLNA". For a biotech company, a name change often signals a strategic pivot or a desire to redefine its public image and scientific mission. The company explicitly states this rebrand reflects a strategic focus on developing novel medicines to modulate the filamin A protein for central nervous system disorders, particularly TSC-related epilepsy. This clarifies their R&D direction and could help investors understand the company's future pipeline focus. The change also potentially allows the company to distance itself from any past associations.